Dergiler / The Anatolian Journal of Cardiology / 2018 / Cilt: 19 - Sayı: 5

Rationale, Design, and Methodology of the APOLLON trial: A comPrehensive, ObservationaL registry of heart faiLure with midrange and preserved ejectiON fraction

Sayfa
311–318
DOI
—
🏛️Bu makalenin bibliyografik verileri ve tam metin bağlantısı DergiPark üzerinden sağlanmıştır.
DergiPark Kaydı ↗
✨

Yapay Zeka Hızlı Bakış & Çıkarımlar

AI Insight
⚡ TL;DR(1 Cümlede Hızlı Çıkarım)

Demographic, lifestyle, medical, and therapeutic data will be collected by this specificsurvey.Conclusion: The APOLLON trial will be the largest and most comprehensive study in Turkey evaluating HF patients with a LVEF ≥40% and will alsobe the first study to specifically analyze the recently designated HFmrEF category.

📌 3 Maddede Bu Makale

🎯
Amaç & Hipotez:Objective: Although almost half of chronic heart failure (HF) patients have mid-range (HFmrEF) and preserved left-ventricular ejection fraction(HFpEF), no studies have been carried out with these patients in our country.
📊
Temel Bulgular & Veri:The study population will include 1065 patients from 12 sites inTurkey.
💡
Sonuç & Katkı:Demographic, lifestyle, medical, and therapeutic data will be collected by this specificsurvey.Conclusion: The APOLLON trial will be the largest and most comprehensive study in Turkey evaluating HF patients with a LVEF ≥40% and will alsobe the first study to specifically analyze the recently designated HFmrEF category.
🔬Tür:Uygulamalı Anket & Alan Araştırması
📍Kapsam:Genişletilmiş Akademik Örneklem
⚙️Değişkenler:Alan Parametreleri

Özet

Objective: Although almost half of chronic heart failure (HF) patients have mid-range (HFmrEF) and preserved left-ventricular ejection fraction(HFpEF), no studies have been carried out with these patients in our country. This study aims to determine the demographic characteristics andcurrent status of the clinical background of HFmrEF and HFpEF patients in a multicenter trial.Methods: A comPrehensive, ObservationaL registry of heart faiLure with mid-range and preserved ejectiON fraction (APOLLON) trial will bean observational, multicenter, and noninterventional study conducted in Turkey. The study population will include 1065 patients from 12 sites inTurkey. All data will be collected at one point in time and the current clinical practice will be evaluated (ClinicalTrials.gov number NCT03026114).Results: We will enroll all consecutive patients admitted to the cardiology clinics who were at least 18 years of age and had New York HeartAssociation class II, III, or IV HF, elevated brain natriuretic peptide levels within the last 30 days, and an left ventricular ejection fraction (LVEF)of at least 40%. Patients fulfilling the exclusion criteria will not be included in the study. Patients will be stratified into two categories accordingto LVEF: mid-range EF (HFmrEF, LVEF 40%-49%) and preserved EF (HFpEF, LVEF ≥50%). Regional quota sampling will be performed to ensure thatthe sample was representative of the Turkish population. Demographic, lifestyle, medical, and therapeutic data will be collected by this specificsurvey.Conclusion: The APOLLON trial will be the largest and most comprehensive study in Turkey evaluating HF patients with a LVEF ≥40% and will alsobe the first study to specifically analyze the recently designated HFmrEF category.

🔖

Bu Makaleye Atıf Yap

ÖZLEK, B., ÖZLEK, E., ÇELİK, O., CİL, C., DOĞAN, V., TEKİNALP, M., AGUŞ, H. Z., KAHRAMAN, S., OSKEN, A., RENCÜZOĞULLARI, İ., TANIK, V. O., BEKAR, L., ÇAKIR, M. O., KAYA, B. C., TİBİLLİ, H., ÇELİK, Y., BAŞARAN, Ö., MERT, K. U., SEVİNÇ, S., DEMİRCİ, E., Eng, E. (2018). Rationale, Design, and Methodology of the APOLLON trial: A comPrehensive, ObservationaL registry of heart faiLure with midrange and preserved ejectiON fraction. The Anatolian Journal of Cardiology, Cilt: 19 - Sayı: 5, 311–318. https://ajindex.com/articles/365810

📄 Tam Metin PDF Okuyucu

📄

PDF görüntüleyici hazırlanıyor...

Kaynakça (2)

  1. Kitzman DW, Little WC, Brubaker PH, Anderson RT, Hundley WG, Marburger CT, et al. Patho-physiological characterization of isolated diastolic heart failure in comparison to systolic heart failure. JAMA 2002; 288: 2144-50. [CrossRef] Bursi F, Weston SA, Redfield MM, Jacobsen SJ, Pakhomov S, Nkomo VT, et al. Systolic and diastolic heart failure in the community. JAMA 2006; 296: 2209-16. [CrossRef] Anjan VY, Loftus TM, Burke MA, Akhter N, Fonarow GC, Gheorghiade M, et al. Prevalence, clinical phenotype, and outcomes associated with normal B-type natriuretic peptide levels in heart failure with preserved ejection fraction. Am J Cardiol 2012; 110: 870-6.
  2. Nauta JF, Hummel YM, van Melle JP, van der Meer P, Lam CSP, Ponikowski P, et al. What have we learned about heart failure with midrange ejection fraction one year after its introduction? Eur J Heart Fail 2017; 19: 1569-73. [CrossRef] Lam CS, Solomon SD. The middle child in heart failure: heart failure with mid-range ejection fraction (40-50%). Eur J Heart Fail 2014; 16: 1049-55. [CrossRef] Vedin O, Lam CSP, Koh AS, Benson L, Teng THK, Tay WT, et al. Significance of Ischemic Heart Disease in Patients With Heart Failure and Preserved, Midrange, and Reduced Ejection Fraction: A Nationwide Cohort Study. Circ Heart Fail 2017; 10. pii: e003875. [CrossRef] Chioncel O, Lainscak M, Seferovic PM, Anker SD, Crespo-Leiro MG, Harjola VP, et al. Epidemiology and one-year outcomes in patients with chronic heart failure and preserved, mid-range and reduced ejection fraction: an analysis of the ESC Heart Failure Long-Term Registry. Eur J Heart Fail 2017; 19: 1574-85. [CrossRef] Farmakis D, Simitsis P, Bistola V, Triposkiadis F, Ikonomidis I, Katsanos S, et al. Acute heart failure with mid-range left ventricular ejection fraction: clinical profile, in-hospital management, and short-term outcome. Clin Res Cardiol 2017; 106: 359-68. [CrossRef] Cheng RK, Cox M, Neely ML, Heidenreich PA, Bhatt DL, Eapen ZJ, et al. Outcomes in patients with heart failure with preserved, borderline, and reduced ejection fraction in the Medicare population. Am Heart J 2014; 168: 721-30. [CrossRef] Coles AH, Tisminetzky M, Yarzebski J, Lessard D, Gore JM, Darling CE, et al. Magnitude of and prognostic factors associated with 1-year mortality after hospital discharge for acute decompensated heart failure based on ejection fraction findings. J Am Heart Assoc 2015; 4. pii: e002303. [CrossRef] Tsuji K, Sakata Y, Nochioka K, Miura M, Yamauchi T, Onose T, et a